Navigation Links
BioMed Realty, L.P. Announces Closing of Offering of 3.85% Senior Unsecured Notes Due 2016
Date:3/30/2011

SAN DIEGO, March 30, 2011 /PRNewswire/ -- BioMed Realty Trust, Inc. (NYSE: BMR) today announced that its operating partnership subsidiary, BioMed Realty, L.P., completed a public offering of $400 million aggregate principal amount of 3.85% Senior Notes due 2016 (the "Notes").  The Notes are senior unsecured obligations of the operating partnership and are fully and unconditionally guaranteed by BioMed Realty Trust, Inc.  

Interest on the Notes is payable semiannually on April 15 and October 15, beginning October 15, 2011. The Notes will mature on April 15, 2016.  The Notes were issued at 99.365% of the principal amount, with a coupon of 3.85%, to yield 3.99% to maturity.  The operating partnership intends to use the net proceeds from the offering to repay a portion of the outstanding indebtedness under its unsecured line of credit and for other general corporate and working capital purposes.

The registration statement relating to these securities has become effective by rule of the Securities and Exchange Commission.  This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of these securities, nor shall there be any sale of such securities in any state or other jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities, blue sky, or other laws of such state or other jurisdiction. Wells Fargo Securities, LLC, KeyBanc Capital Markets Inc., and Morgan Stanley & Co. Incorporated acted as Joint Book Running Managers for the offering.  A final prospectus supplement related to the offering was filed with the Securities and Exchange Commission on March 24, 2011.  A copy of the final prospectus supplement may be obtained by contacting Wells Fargo Securities, LLC, 1525 West W.T. Harris Blvd., NC0675, Charlotte, North Carolina 28262, Attention: Syndicate Operations or by calling toll-free at 1-800-326-5897; KeyBanc Capital Markets Inc., 127 Public Square, 4th Floor, Cleveland, Ohio 44114  or by calling toll-free at 1-866-227-6479; or Morgan Stanley & Co. Incorporated, 180 Varick Street, New York, NY 10014, Attention: Prospectus Department, by calling toll-free at 1-866-718-1649 or by email at prospectus@morganstanley.com.  

About BioMed Realty Trust

BioMed Realty Trust, Inc. is a real estate investment trust (REIT) focused on Providing Real Estate to the Life Science Industry®. The company's tenants primarily include biotechnology and pharmaceutical companies, scientific research institutions, government agencies and other entities involved in the life science industry. BioMed owns or has interests in 85 properties, representing 147 buildings with approximately 12.2 million rentable square feet. The company's properties are located predominantly in the major U.S. life science markets of Boston, San Diego, San Francisco, Seattle, Maryland, Pennsylvania and New York/New Jersey, which have well-established reputations as centers for scientific research.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 based on current expectations, forecasts and assumptions that involve risks and uncertainties that could cause actual outcomes and results to differ materially. These risks and uncertainties include, without limitation: general risks affecting the real estate industry (including, without limitation, the inability to enter into or renew leases, dependence on tenants' financial condition, and competition from other developers, owners and operators of real estate); adverse economic or real estate developments in the life science industry or the company's target markets; risks associated with the availability and terms of financing, the use of debt to fund acquisitions and developments, and the ability to refinance indebtedness as it comes due; failure to maintain the company's investment grade credit ratings with the ratings agencies; failure to manage effectively the company's growth and expansion into new markets, or to complete or integrate acquisitions and developments successfully; reductions in asset valuations and related impairment charges; risks and uncertainties affecting property development and construction; risks associated with downturns in the national and local economies, increases in interest rates, and volatility in the securities markets; potential liability for uninsured losses and environmental contamination; risks associated with the company's potential failure to qualify as a REIT under the Internal Revenue Code of 1986, as amended, and possible adverse changes in tax and environmental laws; and risks associated with the company's dependence on key personnel whose continued service is not guaranteed. For a further list and description of such risks and uncertainties, see the reports filed by the company with the Securities and Exchange Commission, including the company's most recent annual report on Form 10-K and quarterly reports on Form 10-Q. The company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE BioMed Realty Trust, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Boston University Biomedical Engineers Find Chink in Bacterias Armor
2. Nobel Prize Awarded to Foundation for Biomedical Research Board Member
3. Saladax Biomedicals 5-FU Personalized Chemotherapy Management (PCM(R)) Assay CE Marked for Distribution in the EU
4. Synapse Biomedical Receives FDA Approval of NeuRx Diaphragm Pacing System (DPS)(TM) For Spinal Cord Injury Breathing Applications
5. The Foundation for Biomedical Research Announces Winners of the 7th Annual Michael E. DeBakey Journalism Awards
6. NIH Funds New Wellstone Research Center for Muscular Dystrophy at Boston Biomedical Research Institute
7. OmegaGenesis Unveils Novel Nanotechnology Platform With Broad Biomedical Applications
8. Oramed Pharmaceuticals to Present at the 8th National Life Science & Technology Week ILSI -BIOMED Conference, Israel 2009
9. Subsidiary of Nova Biomedical Completes Acquisition of Assets of CCS Medicals Subsidiary, Sanvita, Inc.
10. Voler Systems President Speaks at BIOMEDevice San Jose
11. Nominations Open for the 2010 Dr. Paul Janssen Award for Biomedical Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... 23, 2016 Bracket , a leading clinical ... generation clinical outcomes platform, Bracket eCOA (SM) 6.0, at ... 26 – 30, 2016 in Philadelphia , ... Outcome Assessment product of its kind to fully integrate with ... Bracket eCOA 6.0 is a flexible platform for electronic clinical ...
(Date:6/23/2016)... and INDIANAPOLIS , June ... receiving a Lilly Diabetes Tomorrow,s Leaders Scholarship is any ... scholarship winners, announced today online at www.diabetesscholars.org ... type 1 diabetes stand in the way of academic ... supported the Foundation,s scholarship program since 2012, and continues ...
(Date:6/23/2016)... 2016 Revolutionary technology includes multi-speaker ... , industry leaders in advanced audiology and hearing aid ... Opn ™, the world,s first internet connected hearing aid ... devices.      (Photo: http://photos.prnewswire.com/prnh/20160622/382240 ) ... of ,world firsts,: , TwinLink™ - the ...
Breaking Medicine Technology:
(Date:6/24/2016)... ... 2016 , ... To succeed under value-based payments, healthcare providers ... how to move forward, given the need to sustain current operations. PYA has ... an organization’s specific needs. , PYA Principal Martie Ross states, “Healthcare providers want ...
(Date:6/24/2016)... Brooklyn, New York (PRWEB) , ... June 24, 2016 , ... ... medical marijuana patients optimize the ingestion of their medication by matching users with high ... allows users to compare pieces with no commitment. , Inhale was founded by two ...
(Date:6/24/2016)... ... ... Dr. Seema Daulat, a native Texan and University of Texas at Austin ... July 13, 2016. , Dr. Daulat earned her Doctorate of Medicine (MD) at The ... the Agape Clinic serving Dallas’ underprivileged community. , Following medical school, Dr. Daulat completed ...
(Date:6/23/2016)... Los Angeles, CA (PRWEB) , ... June 23, 2016 , ... ... being conducted that may expose a possible link between head and neck cancer in ... individuals participating in the study were evaluated based on whether they had gum disease, ...
(Date:6/23/2016)... ... ... The Mechille Wilson Agency, a Texas-based insurance company that provides coverage to hundreds ... a charity drive to assist a student to be chosen from the local area. ... be presented to the chosen student to help with the growing costs of tuition, ...
Breaking Medicine News(10 mins):